BioSpace News Archive

aTyr Pharma Inc. (Nasdaq:LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel immunological pathways, today announced positive data from its Phase 1 clinical trial of ATYR1923, an immuno-modulatory therapeutic candidate with potentially broad therapeutic application in the treatment of interstitial lung diseases.

7 Hills Pharma announced the formation of its Scientific Advisory Board (SAB).

The American Health Council has selected Valerie McRae, MD to its Board of Physicians.

Cognition Therapeutics, Inc. announced that the first patient has been dosed in the SNAP (AβO Displacement from Synapses on Neurons in Alzheimer’s Patients) Study of Elayta™ (CT1812)

Distinguished 25-year career serving at the U.S. Food and Drug Administration, including 15 years of senior leadership in CDER and OND

PharmaCyte Biotech, Inc. (OTCQB: PMCB) is closing in on what will be a landmark event in this small company’s history—a clinical trial in the United States under the watchful eye of the most powerful drug regulatory agency in the world

Operations are Anticipated to Continually Increase, Which Includes Volume and Pricing, While it Prepares to Launch Its More Profitable Aggregate Operations

Ancient, central role of brain peptide TCAP in maintenance of brain health elucidated in publications in Cell, Nature Communications, and the Journal of Neuro-endocrinology

Trial supports Actinium’s strategic expansion of its CD33 program into novel combinations that can lead to increased use of bone marrow transplants and expand the addressable patient population for this program

Catalyst Pharmaceuticals, Inc. announced the appointment of Daniel J. Brennan as Chief Commercial Officer.